Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Proteomics plus RNA-seq in advanced melanoma samples treated with anti-PD1 immunotherapy unravel resistance mechanisms

Date

02 Mar 2020

Session

Poster Display & Cocktail

Presenters

Guillermo Prado

Citation

Annals of Oncology (2020) 31 (suppl_1): S1-S7. 10.1016/annonc/annonc86

Authors

G. Prado1, A. Gámez Pozo2, L. Trilla Fuertes1, A. Zapater Moros1, E. López Camacho1, R. López Vacas3, M. Díaz Almirón4, P. Zamora5, J.A. Fresno Vara2, E. Espinosa2

Author affiliations

  • 1 R+d, Biomedica Molecular Medicine, 28049 - Madrid/ES
  • 2 Laboratorio De Oncología Traslacional, Hospital Universitario La Paz, 28046 - Madrid/ES
  • 3 Molecular Oncology, Hospital Universitario La Paz, 28046 - Madrid/ES
  • 4 Biostatistics Unit, Hospital Universitario La Paz, 28046 - Madrid/ES
  • 5 Hospital Universitario La Paz, 28036 - Madrid/ES
More

Resources

Melanoma is the most lethal malignancy of the skin. Immunotherapy has contributed to improved survival in melanoma patients, yet the mechanisms explaining differences in efficacy have not been elucidated. In previous studies our group found an immune signature that predicts response to antiPD1 immunotherapy. On the other hand, melanoma genomics have been extensively studied, but data regarding protein expression are still scarce. We have performed a genomics plus proteomics analysis of advanced melanoma samples aiming to find mechanisms of resistance to antiPD1.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings